Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel C Mok

Showing results (121-130 of 144) with videos related to

Pageof 15
Sort By:
Cancer Research|November 17, 2005
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovaryTomas Bonome, Ji-Young Lee, Dong-Choon Park, et al.
Cancers|February 9, 2021
Correction: Hu, W., et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. <i>Cancers</i> 2020, <i>12</i>, 2436Wen Hu, Li Zhang, Sammy Ferri-Borgogno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 25, 2013
Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancerTarrik M Zaid, Tsz-Lun Yeung, Melissa S Thompson, et al.
Cancers|March 13, 2024
Molecular, Metabolic, and Subcellular Mapping of the Tumor Immune Microenvironment via 3D Targeted and Non-Targeted Multiplex Multi-Omics AnalysesSammy Ferri-Borgogno, Jared K Burks, Erin H Seeley, et al.
Cell|November 7, 2002
BRCA1 supports XIST RNA concentration on the inactive X chromosomeShridar Ganesan, Daniel P Silver, Roger A Greenberg, et al.
Oncotarget|September 24, 2015
KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1Mei-Ting Qiu, Qiong Fan, Zhu Zhu, et al.
Cancers|September 2, 2020
Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant PhenotypeWen Hu, Li Zhang, Sammy Ferri-Borgogno, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 11, 2022
Ryanodine receptor 1-mediated Ca<sup>2+</sup> signaling and mitochondrial reprogramming modulate uterine serous cancer malignant phenotypesLi Zhang, Chi-Lam Au-Yeung, Chunxian Huang, et al.
Oncotarget|November 18, 2015
Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancerKim Moran-Jones, Brian S Gloss, Rajmohan Murali, et al.
Molecular Cancer Research : MCR|April 17, 2023
Comparative Tumor Microenvironment Analysis of Primary and Recurrent Ovarian Granulosa Cell TumorsEleonora Khlebus, Veena K Vuttaradhi, Thomas Welte, et al.
Pageof 15

Showing results (121-130 of 144) with videos related to

Sort By:
Pageof 15
Cancer Research|November 17, 2005
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovaryTomas Bonome, Ji-Young Lee, Dong-Choon Park, et al.
Cancers|February 9, 2021
Correction: Hu, W., et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. <i>Cancers</i> 2020, <i>12</i>, 2436Wen Hu, Li Zhang, Sammy Ferri-Borgogno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 25, 2013
Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancerTarrik M Zaid, Tsz-Lun Yeung, Melissa S Thompson, et al.
Cancers|March 13, 2024
Molecular, Metabolic, and Subcellular Mapping of the Tumor Immune Microenvironment via 3D Targeted and Non-Targeted Multiplex Multi-Omics AnalysesSammy Ferri-Borgogno, Jared K Burks, Erin H Seeley, et al.
Cell|November 7, 2002
BRCA1 supports XIST RNA concentration on the inactive X chromosomeShridar Ganesan, Daniel P Silver, Roger A Greenberg, et al.
Oncotarget|September 24, 2015
KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1Mei-Ting Qiu, Qiong Fan, Zhu Zhu, et al.
Cancers|September 2, 2020
Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant PhenotypeWen Hu, Li Zhang, Sammy Ferri-Borgogno, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 11, 2022
Ryanodine receptor 1-mediated Ca<sup>2+</sup> signaling and mitochondrial reprogramming modulate uterine serous cancer malignant phenotypesLi Zhang, Chi-Lam Au-Yeung, Chunxian Huang, et al.
Oncotarget|November 18, 2015
Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancerKim Moran-Jones, Brian S Gloss, Rajmohan Murali, et al.
Molecular Cancer Research : MCR|April 17, 2023
Comparative Tumor Microenvironment Analysis of Primary and Recurrent Ovarian Granulosa Cell TumorsEleonora Khlebus, Veena K Vuttaradhi, Thomas Welte, et al.
Pageof 15